文献速递血栓与止血

人血小板表达内皮细胞蛋白C受体,可用于增强因子VIIa活性的定位

Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity.
PubMed 文献 · J Thromb Haemost · 2018-06-27

本研究探讨因子VIIa与活化血小板结合机制,发现人血小板表达内皮细胞蛋白C受体(EPCR),过量蛋白C或抗EPCR抗体可部分抑制因子VIIa及FVIIa-DVQ的血小板结合并降低其促凝血活性,增强EPCR结合足以解释FVIIa-DVQ较野生型因子VIIa血小板结合增加。

要点

  • 人血小板表达EPCR,为首次证实。
  • 过量蛋白C或抗EPCR抗体部分抑制因子VIIa与FVIIa-DVQ的血小板结合。
  • 结合减少对应因子Xa和凝血酶生成活性下降。

核心结论

  • 人血小板表达EPCR,调控EPCR结合或可增强合理设计的因子VIIa类似物的止血效力。

研究设计与样本

  • 采用流式细胞术、免疫荧光、免疫沉淀和质谱分析研究人血小板与因子VIIa及FVIIa-DVQ的结合。

主要发现

  • 过量蛋白C或抗EPCR抗体存在时,因子VIIa和FVIIa-DVQ的血小板结合均被部分抑制,且因子Xa和凝血酶生成活性相应降低。
  • 增强的EPCR结合足以解释FVIIa-DVQ相比野生型因子VIIa增加的血小板结合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Factor VIIa binds activated platelets to promote hemostasis in hemophilia patients with inhibitors. The interactions and sites responsible for platelet-FVIIa binding are not fully understood. Endothelial cell protein C receptor (EPCR) is expressed on activated human platelets. EPCR binding enhances the efficacy of a FVIIa variant and could impact design of new therapeutics. SUMMARY: Background High-dose factor VIIa (FVIIa) is routinely used as an effective bypassing agent to treat hemophilia patients with inhibitory antibodies that compromise factor replacement. However, the mechanism by which FVIIa binds activated platelets to promote hemostasis is not fully understood. FVIIa-DVQ is an analog of FVIIa with enhanced tissue factor (TF)-independent activity and hemostatic efficacy relative to FVIIa. Our previous studies have shown that FVIIa-DVQ exhibits greater platelet binding, thereby suggesting that features in addition to lipid composition contribute to platelet-FVIIa interactions. Objectives Endothelial cell protein C receptor (EPCR) also functions as a receptor for FVIIa on endothelial cells. We therefore hypothesized that an interaction with EPCR might play a role in platelet-FVIIa binding. Methods/results In the present study, we used flow cytometric analyses to show that platelet binding of both FVIIa and FVIIa-DVQ is partially inhibited in the presence of excess protein C or an anti-EPCR antibody. This decreased binding results in a corresponding decrease in the activity of both molecules in FXa and thrombin generation assays. Enhanced binding to EPCR was sufficient to account for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa. As EPCR protein expression has not previously been shown in platelets, we confirmed the presence of EPCR in platelets using immunofluorescence, flow cytometry, immunoprecipitation, and mass spectrometry. Conclusions This work represents the first demonstration that human platelets express EPCR and suggests that modulation of EPCR binding could be utilized to enhance the hemostatic efficacy of rationally designed FVIIa analogs.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Fager AM, Machlus KR, Ezban M, et al. Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. J Thromb Haemost. 2018. PMID: 29879294. doi:10.1111/jth.14165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。